Literature DB >> 1979977

Monoclonal anti-P-glycoprotein antibody-dependent killing of multidrug-resistant tumor cells by human mononuclear cells.

Y Heike1, H Hamada, N Inamura, S Sone, T Ogura, T Tsuruo.   

Abstract

Mouse monoclonal antibodies (MRK16 and MRK17) against human multidrug-resistant cancer cell lines were tested for antibody-dependent cytotoxicity mediated by human blood mononuclear cells, using a 4-h 51Cr release assay. MRK16 (IgG2a isotype) was shown to be more effective than MRK17 (IgG1 isotype). Moreover, when four pairs of drug-resistant and their parent sensitive human cancer cells were tested for antibody-dependent cell-mediated cytolysis (ADCC) using MRK16, only the drug-resistant cell lines were susceptible to ADCC reaction. When highly purified lymphocytes (greater than 99%) and monocytes (greater than 97%) were isolated from blood mononuclear cells by centrifugal elutriation and adherence, MRK16 promoted both lymphocyte- and monocyte-mediated tumor cell killing, whereas MRK17 induced only a lymphocyte-mediated ADCC reaction. These results suggest that MRK16 of IgG2a subtype may be a useful therapeutic agent in eradication of drug-resistant cancer cells expressing P-glycoprotein through ADCC reaction.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1979977      PMCID： PMC5917982          DOI： 10.1111/j.1349-7006.1990.tb02528.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  39 in total

1.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

2.  Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells.

Authors:  H Hamada; T Tsuruo
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

3.  Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.

Authors:  T Utsugi; S Sone
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

4.  Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.

Authors:  A Eisenthal; R B Cameron; I Uppenkamp; S A Rosenberg
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

5.  Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma.

Authors:  H F Sears; D Herlyn; Z Steplewski; H Koprowski
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

6.  Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells.

Authors:  Z Steplewski; M D Lubeck; H Koprowski
Journal:  Science       Date:  1983-08-26       Impact factor: 47.728

7.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Induction by interferon-alpha of tumoricidal activity of adherent mononuclear cells from human blood: monocytes as responder and effector cells.

Authors:  S Sone; T Utsugi; T Shirahama; K Ishii; S Mutsuura; M Ogawara
Journal:  J Biol Response Mod       Date:  1985-04

9.  Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells.

Authors:  A R Safa; C J Glover; M B Meyers; J L Biedler; R L Felsted
Journal:  J Biol Chem       Date:  1986-05-15       Impact factor: 5.157

10.  Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells.

Authors:  G Schulz; L K Staffileno; R A Reisfeld; G Dennert
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307
View more
  12 in total

1.  Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.

Authors:  E B Mechetner; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 2.  Antibody-directed therapy of multidrug-resistant tumor cells.

Authors:  T Efferth; M Volm
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 3.  Antibodies in the study of multiple drug resistance.

Authors:  Y Heike; T Tsuruo
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Polymorphonuclear leukocytes-mediated lysis of A431 cells induced by IgG1 mouse anti-epidermal growth factor receptor monoclonal antibodies.

Authors:  T Kawamoto; K Kishimoto; K Takahashi; T Matsumura; J D Sato; S Taniguchi
Journal:  In Vitro Cell Dev Biol       Date:  1992 Nov-Dec

Review 5.  Mechanisms of Drug Resistance in Veterinary Oncology- A Review with an Emphasis on Canine Lymphoma.

Authors:  Maurice Zandvliet; Erik Teske
Journal:  Vet Sci       Date:  2015-08-12

6.  Transduction of the macrophage colony-stimulating factor gene into human multidrug resistant cancer cells: enhanced therapeutic efficacy of monoclonal anti-P-glycoprotein antibody in nude mice.

Authors:  S Sone; T Tsuruo; S Sato; S Yano; Y Nishioka; T Shinohara
Journal:  Jpn J Cancer Res       Date:  1996-07

7.  Treatment resistance mechanisms of malignant glioma tumor stem cells.

Authors:  Philip G R Schmalz; Michael J Shen; John K Park
Journal:  Cancers (Basel)       Date:  2011-02-10       Impact factor: 6.639

8.  Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.

Authors:  S Yano; S Sone; Y Nishioka; M Naito; T Tsuruo; T Ogura
Journal:  Jpn J Cancer Res       Date:  1994-02

9.  Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16.

Authors:  M Naito; H Tsuge; C Kuroko; A Tomida; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1993-05

10.  Effector cell analysis of human multidrug-resistant cell killing by mouse-human chimeric antibody against P-glycoprotein.

Authors:  Y Nishioka; S Sone; Y Heike; H Hamada; K Ariyoshi; T Tsuruo; T Ogura
Journal:  Jpn J Cancer Res       Date:  1992-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.